Elicio Therapeutics announces 2026 annual meeting
- Annual meeting on November 12, 2026
- Three directors to be elected
- Baker Tilly US, LLP to be ratified as auditor
ELTX
Elicio Therapeutics, Inc. SEC filings
Every EDGAR filing for Elicio Therapeutics, Inc. (ELTX), newest first, with AI summaries and stories.
- Ticker
- ELTX
- CIK
- 1601485
- Latest filing
- Oct 9
Next: earnings expected ~Nov 13 · 10-Q expected ~Nov 13 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINEDEF 14AElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE4Elicio Therapeutics, Inc.ELTXLIVE 7 insider filings
Julian Adams, insider filing for ELTX
Show all 7
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
Julian Adams, reporting
NOTABLE10-QElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE4Elicio Therapeutics, Inc.ELTXLIVE 4 insider filings
Christopher Haqq, insider filing for ELTX
Show all 4
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
Christopher Haqq, reporting
ROUTINESCHEDULE 13GElicio Therapeutics, Inc.ELTXLIVE Ownership stake disclosure by Moti Investments LLC
Moti Investments LLC, filed by
ROUTINESCHEDULE 13G/AElicio Therapeutics, Inc.ELTXLIVE Ownership stake disclosure by Knoll Capital Management, LLC (amended)
Knoll Capital Management, LLC, filed by
ROUTINE424B5Elicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE NOTABLE10-QElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE10-K/AElicio Therapeutics, Inc.ELTXLIVE ROUTINEEFFECTElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE424B5Elicio Therapeutics, Inc.ELTXLIVE ROUTINES-8Elicio Therapeutics, Inc.ELTXLIVE ROUTINES-3/AElicio Therapeutics, Inc.ELTXLIVE NOTABLE10-KElicio Therapeutics, Inc.ELTXLIVE ROUTINE8-KElicio Therapeutics, Inc.ELTXLIVE ROUTINES-3/AElicio Therapeutics, Inc.ELTXLIVE ROUTINE4Elicio Therapeutics, Inc.ELTXLIVE 4 insider filings
Robert Connelly, insider filing for ELTX
Show all 4
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
- 4Insider filing for ELTX
Robert Connelly, reporting
ROUTINE4Elicio Therapeutics, Inc.ELTXLIVE Peter DeMuth, insider filing for ELTX
Peter DeMuth, reporting
ROUTINEEFFECTElicio Therapeutics, Inc.ELTXLIVE ROUTINES-3Elicio Therapeutics, Inc.ELTXLIVE Elicio Therapeutics, Inc. (ELTX) has filed an S-3 registration statement to efficiently raise capital by offering various securities to the public.
NOTABLE10-QElicio Therapeutics, Inc.ELTXLIVE Elicio Therapeutics, Inc. (ELTX) filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational progress.
MAJOR8-KElicio Therapeutics, Inc.ELTXLIVE Elicio Therapeutics, Inc. (ELTX) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change comes at a critical juncture as the company navigates the development and commercialization of its pipeline of novel…